Oct. 24, 2025: State Advocacy Update

| 1 Min Read
Contents
  1. New issue brief provides kratom and tianeptine basics, AMA recommendations
  2. More articles in this issue

New issue brief provides kratom and tianeptine basics, AMA recommendations

A new issue brief (PDF) from the AMA Advocacy Resource Center provides key information about kratom and tianeptine—two unregulated substances that have generated increasing reports of public health harms. The issue brief includes basic information about the substances, including the fact that neither has been approved by the U.S. Food and Drug Administration.

Haven't subscribed?

Stay current on the latest on the issues impacting physicians, patients and the health care environment with the AMA’s Advocacy Update newsletter.

Sign Up/Create Account

The AMA recommends the safety and efficacy of kratom should be determined through research and clinical trials and subsequently evaluated by the relevant regulatory entities for its appropriateness for sale and potential oversight via the Controlled Substances Act, before it can be marketed, purchased or prescribed. The AMA also advocates to ban the sale of tianeptine directly to the public in the absence of research into the safety and efficacy of the substance. 

Your Powerful Ally

The AMA is your powerful ally, focused on addressing the issues important to you, so you can focus on what matters most—patients. We will meet this challenge together.

Join Us

FEATURED STORIES

Open palm and health care icons

Want to turn your physician expertise into enterprise? Apply now

| 3 Min Read
Parent holds young child during doctor's appointment

New CMS model brings ACO approach to care for kids at high risk

| 5 Min Read
Heart shape plate with healthy salad surrounded by fruit and vegetables

Why nutrition education must become core training for physicians

| 4 Min Read
Team of doctors diagnose giant human blood vessel

What doctors wish patients knew about the deadly risk of stroke

| 15 Min Read